CNBX Pharmaceuticals Inc.
CNBX
$0.0024
$0.000420.00%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -91.87% | -68.31% | -32.39% | 1,700.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -91.87% | -68.31% | -32.39% | 1,700.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.00% | -93.11% | -69.82% | -34.22% | 1,680.00% |
| SG&A Expenses | -49.71% | -47.57% | -43.03% | -48.44% | -46.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -75.56% | -61.09% | -46.84% | -41.94% | -27.99% |
| Operating Income | 57.03% | 40.78% | 37.40% | 44.56% | 58.31% |
| Income Before Tax | 76.03% | 84.39% | 81.26% | 66.59% | 70.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 76.03% | 84.39% | 81.26% | 66.59% | 70.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.03% | 84.39% | 81.26% | 66.59% | 70.26% |
| EBIT | 57.03% | 40.78% | 37.40% | 44.56% | 58.31% |
| EBITDA | 51.91% | 33.59% | 33.60% | 46.05% | 63.27% |
| EPS Basic | 83.88% | 98.72% | 98.62% | 97.74% | 97.72% |
| Normalized Basic EPS | 76.40% | 90.83% | 95.55% | 96.64% | 97.04% |
| EPS Diluted | 83.88% | 98.72% | 98.62% | 97.75% | 97.73% |
| Normalized Diluted EPS | 76.40% | 90.83% | 95.55% | 96.64% | 97.04% |
| Average Basic Shares Outstanding | 37.48% | 99.86% | 238.86% | 724.54% | 1,504.41% |
| Average Diluted Shares Outstanding | 37.48% | 99.86% | 238.86% | 724.54% | 1,504.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |